Iaşi-based drug maker Antibiotice, a major player in the drugindustry, in the first half posted net income worth 17.2m RON (4.2meuros), up almost 15% from a year ago.
At the end of the first half, turnover reached 115.8m RON (27.6meuros), 7.2% more than a year ago.
The turnover trend was largely triggered by exports, which jumpedby 35% to around 26m RON (6.3m euros). On the other hand, domesticsales amounted to 89.9m RON, up 1.2%.
As for exports, the company got the necessary licenses from the USFood and Drug Administration to start deliveries of injectableampicillin to the US. In the first six months, Antibioticedelivered around 300,000 ampoules on this market.
"Over the next three years, Antibiotice wants to developinternational projects with eight partners, leading to a majorincrease in exports," reads the company's report.
In 2009, exports generated 18.5% of Antibiotice revenues, but thecompany plans to reach a 25% weight in the next three years.
In 2010-2012, the company plans to launch 64 prescription drugs and17 OTCs and nutritional supplements.
"By late 2010, Antibiotice wants to boost turnover by 10% anddomestic sales by 18%, retaining the 4th position among Romania'sgenerics produces, and also to step up exports," Antibiotice reportalso reads.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
